Lista de obras - M Galluzzo - Dominio Público Uruguay

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

artículo científico publicado en 2020

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab

artículo científico publicado en 2018

A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab

artículo científico publicado en 2020

A safety evaluation of guselkumab for the treatment of psoriasis

artículo científico publicado en 2018

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.

artículo científico publicado en 2017

Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.

artículo científico publicado en 2016

Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature

artículo científico publicado en 2019

Brodalumab for the treatment of psoriasis

artículo científico publicado en 2016

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

artículo científico publicado en 2020

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

artículo científico publicado en 2020

Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients

artículo científico publicado en 2017

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

artículo científico publicado en 2018

Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessm

scholarly article by Mario Puviani et al published 20 September 2018 in International Journal of STD & AIDS

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

artículo científico publicado en 2013

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.

artículo científico publicado en 2016

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study

artículo científico publicado en 2017

HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis

artículo científico publicado en 2016

High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C06:02-positive psoriatic patients: HLA-C06:02/HLA-C*04, in response to ustekinumab

artículo científico publicado en 2019

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

artículo científico publicado en 2015

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

scientific article published on 27 November 2020

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

artículo científico publicado en 2019

Linear psoriasis following the typical distribution of the sciatic nerve.

artículo científico publicado en 2015

Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature

artículo científico publicado en 2015

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.

artículo científico publicado en 2013

New insight into the pathogenesis of nail psoriasis and overview of treatment strategies

artículo científico publicado en 2017

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

article

Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis

artículo científico publicado en 2017

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections

artículo científico publicado en 2017

Pharmacotherapeutic management of psoriasis in adolescents and children

scientific article published on 04 July 2019

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study

artículo científico publicado en 2018

Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab

article

Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers

scientific article published on 01 April 2020

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.

artículo científico publicado en 2017

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

artículo científico publicado en 2018

Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo

artículo científico publicado en 2020

Skin immunity and its dysregulation in psoriasis

scientific article published on 15 August 2019

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

article

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

artículo científico publicado en 2020

Successful treatment of psoriatic crumbly nails with ustekinumab

scientific article published on 21 April 2019

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

artículo científico publicado en 2017

The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis

scientific article published on 11 September 2019

Tildrakizumab for treating psoriasis.

artículo científico publicado en 2017

Tofacitinib for the treatment of psoriasis

artículo científico publicado en 2016

Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy

artículo científico publicado en 2018

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

scientific article published on 09 July 2020

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience

artículo científico publicado en 2019

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

scientific article published on 26 September 2013

What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.

artículo científico publicado en 2014

Lista de obras de M Galluzzo

<i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT, DDX58</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab

A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab

A safety evaluation of guselkumab for the treatment of psoriasis

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.

Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.

Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature

Brodalumab for the treatment of psoriasis

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessm

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study

HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis

High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

Linear psoriasis following the typical distribution of the sciatic nerve.

Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.

New insight into the pathogenesis of nail psoriasis and overview of treatment strategies

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections

Pharmacotherapeutic management of psoriasis in adolescents and children

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study

Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab

Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo

Skin immunity and its dysregulation in psoriasis

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

Successful treatment of psoriatic crumbly nails with ustekinumab

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis

Tildrakizumab for treating psoriasis.

Tofacitinib for the treatment of psoriasis

Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.

High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C06:02-positive psoriatic patients: HLA-C06:02/HLA-C*04, in response to ustekinumab